


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (*original*) A compound of Formula I:



wherein

R^1 , R^2 and R^3 are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or R^1 and R^2 , taken together, form methylenedioxy, ethylenedioxy or propylenedioxy;

R^3 is hydrogen or alkyl of 1 to 6 carbon atoms;




m is 1 to 3;

n is 1 or 2;

p is 0 to 3

with the proviso that when p is 0, both m and n may not be 2;

Q is a heteroaryl moiety chosen from:



R^4 , R^5 , R^6 and R^7 are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms;

X is NR^8 , O or S; and

R^8 is hydrogen or alkyl of 1 to 6 carbon atoms;
or a pharmaceutically acceptable salt thereof.

2. (*original*) A compound according to claim 1, wherein R^1 and R^2 are, independently, hydrogen, halo, cyano, carboxamido, trifluoromethyl, amino, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms.
3. (*original*) A compound according to claim 1, wherein R^1 is alkoxy of one to six carbon atoms and is attached to position 8 of the benzodioxan moiety.
4. (*original*) A compound according to claim 1, wherein R^2 is hydrogen.
5. (*original*) A compound according to claim 1, wherein R^4 , R^5 , R^6 and R^7 are independently hydrogen, halo, cyano, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms.
6. (*original*) A compound according to claim 1, wherein R^4 , R^5 , R^6 and R^7 are independently hydrogen, halo or cyano.
7. (*original*) A compound according to claim 1, wherein m and n are, independently 1 or 2.
8. (*original*) A compound according to claim 1, wherein m is 1 and n is 2.
9. (*original*) A compound according to claim 1, wherein p is 0 or 1.
10. (*original*) A compound according to claim 1, wherein p is 0.

11. **(original)** A compound according to claim 1, wherein X is NR⁸ and R⁸ hydrogen or alkyl of 1 to 3 carbons.
12. **(original)** A compound according to claim 1, wherein R³ is hydrogen or alkyl of 1 to 3 carbons.
13. **(currently amended)** A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a ~~pharma-ceutically~~ pharmaceutically acceptable salt thereof.
14. **(original)** A compound according to claim 1, wherein said compound is N-[(1R,3S)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.
15. **(original)** A compound according to claim 1, wherein said compound is N-[(1S,3R)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.
16. **(original)** A compound according to claim 1, wherein said compound is N-[(trans)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof
17. **(original)** A compound according to claim 1, wherein said compound is N-[(1S,3S)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.
18. **(original)** A compound according to claim 1, wherein said compound is N-[(1R,3R)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.

19. **(original)** A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.
20. **(original)** A compound according to claim 1, wherein said compound is N-[(trans)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amine or a pharmaceutically acceptable salt thereof.
21. **(original)** A compound according to claim 1, wherein said compound is 3-[(cis)-3-({[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amino) cyclopentyl]-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
22. **(original)** A compound according to claim 1, wherein said compound is 3-[(trans)-3-({[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amino)cyclopentyl]-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
23. **(original)** A compound according to claim 1, wherein said compound is 3-[(cis)-3-({[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amino)cyclopentyl]-1-methyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
24. **(original)** A compound according to claim 1, wherein said compound is 3-[(trans)-3-({[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}amino)cyclopentyl]-1-methyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
25. **(original)** A compound according to claim 1, wherein said compound is N-{{(2S)-8-ethoxy-2,3-dihydro-1,4-benzo-dioxin-2-yl]methyl}-N-[(cis)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]amine or a pharmaceutically acceptable salt thereof.
26. **(original)** A compound according to claim 1, wherein said compound is N-{{(2S)-8-ethoxy-2,3-dihydro-1,4-benzo-dioxin-2-yl]methyl}-N-[(trans)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]amine or a pharmaceutically acceptable salt thereof.

27. *(original)* A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, comprising the step of:
- administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
28. *(original)* A method according to claim 27, wherein the condition is depression.
29. *(original)* A method according to claim 27, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
30. *(original)* A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, comprising the step of:
- administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 13.
31. *(original)* A pharmaceutical composition, comprising:
- an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
- a pharmaceutically acceptable carrier or excipient.